分产品来看，安杰思高附加值品类增长显著，GI类产品收入4.13亿元，同比增长23.17%，毛利率提升0.64个百分点至74.65%；EMR/ESD类产品收入1.50亿元，同比+42.85%，毛利率71.15%（同比+4.90个百分点）。财报指出，1. Anjess achieved rapid growth in both revenue and net income in 2024; 2. Overseas market revenue reached 0.333 billion yuan, with a year-on-year increase of 36.19%, significantly higher than the domestic market.
On April 21, the Star Daily reported (special correspondent Gao Qing) that Anjess (688581.SH) released its 2024 earnings report on the evening of April 22. During the reporting period, the company's revenue and net income both saw growth.
The earnings report shows that Anjess achieved a revenue of 0.637 billion yuan in 2024, a year-on-year increase of 25.14%; the net income attributable to shareholders reached 0.293 billion yuan, a year-on-year growth of 35.06%; the net profit excluding non-recurring items was 0.273 billion yuan, a year-on-year increase of 28.62%. The company's operating cash flow net amount is 0.316 billion yuan, with a year-on-year growth of 42.61%.
In terms of products, Anjess's high-value categories saw significant growth, with GI product revenue at 0.413 billion yuan, up 23.17%, and gross margin increased by 0.64 percentage points to 74.65%; EMR/ESD product revenue was 0.15 billion yuan, up 42.85% year-on-year, with a gross margin of 71.15% (up 4.90 percentage points year-on-year). The earnings report pointed out that the rapid growth of EMR/ESD products benefited from product structure optimization and cost control, showing that the company is accelerating its shift towards high-value fields.
Journalists from the Star Daily noted that in the past year, Anjess's overseas market achieved revenue of 0.333 billion yuan, a year-on-year increase of 36.19%, significantly higher than the domestic market (revenue of 0.299 billion yuan, up 14.63% year-on-year), and the overseas gross margin reached 73.21% (up 1.80 percentage points year-on-year).
The earnings report revealed that Anjess's Global Strategy is continuously advancing, with its Netherlands subsidiary already in operation and its USA subsidiary in the preparation stage.
Additionally, Anjess's R&D investment in 2024 was 0.059 billion yuan, a year-on-year increase of 43.53%, with the proportion of revenue rising to 9.30%. The company added 7 new invention patents over the year, holding a total of 100 patents, covering core areas such as bipolar circuit technology, providing support for technological breakthroughs.
As a leading domestic company, Anjess's capacity expansion project for '10 million medical endoscope devices and medical devices per year' has invested 0.88 billion yuan, with progress completed at 44.31%, and is expected to reach production capacity by March 2025.
